Does the media favor VRTX or ALNY?

In the previous week, Vertex Pharmaceuticals had 16 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 30 mentions for Vertex Pharmaceuticals and 14 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 1.24 beat Vertex Pharmaceuticals' score of 0.80 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vertex Pharmaceuticals 16 Very Positive mention(s) 5 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive Alnylam Pharmaceuticals 8 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ALNY or REGN?

In the previous week, Regeneron Pharmaceuticals had 35 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 49 mentions for Regeneron Pharmaceuticals and 14 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 1.24 beat Regeneron Pharmaceuticals' score of 0.65 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 8 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Regeneron Pharmaceuticals 19 Very Positive mention(s) 4 Positive mention(s) 22 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ALNY or ARGX?

In the previous week, Alnylam Pharmaceuticals had 8 more articles in the media than argenex. MarketBeat recorded 14 mentions for Alnylam Pharmaceuticals and 6 mentions for argenex. Alnylam Pharmaceuticals' average media sentiment score of 1.24 beat argenex's score of 0.83 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 8 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive argenex 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ALNY or MRNA?

In the previous week, Moderna had 12 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 26 mentions for Moderna and 14 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 1.24 beat Moderna's score of 0.56 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 8 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 9 Very Positive mention(s) 8 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media favor ALNY or NTRA?

In the previous week, Natera had 5 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 19 mentions for Natera and 14 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 1.24 beat Natera's score of 1.14 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 8 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Natera 11 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Alnylam Pharmaceuticals (ALNY) Competitors

$248.68 +1.17 (+0.47%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$250.12 +1.44 (+0.58%)

As of 09/11/2026 07:30 PM Eastern

Compare

ALNY vs. VRTX, REGN, ARGX, MRNA, and NTRA

Should you buy Alnylam Pharmaceuticals stock or one of its competitors? Alnylam Pharmaceuticals's main competitors and comparable companies include Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), argenex (ARGX), Moderna (MRNA), and Natera (NTRA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Alnylam Pharmaceuticals compare to Vertex Pharmaceuticals?

Vertex Pharmaceuticals (NASDAQ:VRTX) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.

Vertex Pharmaceuticals currently has a consensus price target of $570.83, suggesting a potential upside of 10.75%. Alnylam Pharmaceuticals has a consensus price target of $376.67, suggesting a potential upside of 51.47%. Given Alnylam Pharmaceuticals' higher probable upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Vertex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vertex Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.96
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.88

Vertex Pharmaceuticals has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market.

Vertex Pharmaceuticals has higher revenue and earnings than Alnylam Pharmaceuticals. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vertex Pharmaceuticals	$12.00B	10.90	$3.95B	$17.18	30.00
Alnylam Pharmaceuticals	$3.71B	8.96	$313.75M	$5.38	46.22

Vertex Pharmaceuticals has a net margin of 35.00% compared to Alnylam Pharmaceuticals' net margin of 15.26%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Vertex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vertex Pharmaceuticals	35.00%	23.09%	16.72%
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%

91.0% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 0.2% of Vertex Pharmaceuticals shares are held by company insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Vertex Pharmaceuticals had 16 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 30 mentions for Vertex Pharmaceuticals and 14 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 1.24 beat Vertex Pharmaceuticals' score of 0.80 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vertex Pharmaceuticals	16 Very Positive mention(s)	5 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	8 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Vertex Pharmaceuticals beats Alnylam Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Alnylam Pharmaceuticals compare to Regeneron Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

Alnylam Pharmaceuticals has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market. Comparatively, Regeneron Pharmaceuticals has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market.

Regeneron Pharmaceuticals has higher revenue and earnings than Alnylam Pharmaceuticals. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$3.71B	8.96	$313.75M	$5.38	46.22
Regeneron Pharmaceuticals	$14.34B	5.61	$4.50B	$40.46	19.32

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Alnylam Pharmaceuticals' net margin of 15.26%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Regeneron Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%

In the previous week, Regeneron Pharmaceuticals had 35 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 49 mentions for Regeneron Pharmaceuticals and 14 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 1.24 beat Regeneron Pharmaceuticals' score of 0.65 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	8 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Regeneron Pharmaceuticals	19 Very Positive mention(s)	4 Positive mention(s)	22 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are owned by insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Alnylam Pharmaceuticals currently has a consensus target price of $376.67, indicating a potential upside of 51.47%. Regeneron Pharmaceuticals has a consensus target price of $802.18, indicating a potential upside of 2.65%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Alnylam Pharmaceuticals is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.88
Regeneron Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.58

Summary

Alnylam Pharmaceuticals beats Regeneron Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Alnylam Pharmaceuticals compare to argenex?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and argenex (NASDAQ:ARGX) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability.

Alnylam Pharmaceuticals has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market. Comparatively, argenex has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market.

Alnylam Pharmaceuticals currently has a consensus price target of $376.67, suggesting a potential upside of 51.47%. argenex has a consensus price target of $1,158.61, suggesting a potential upside of 17.70%. Given Alnylam Pharmaceuticals' higher possible upside, equities analysts plainly believe Alnylam Pharmaceuticals is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.88
argenex	0 Sell rating(s)	5 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.88

argenex has higher revenue and earnings than Alnylam Pharmaceuticals. argenex is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$3.71B	8.96	$313.75M	$5.38	46.22
argenex	$4.25B	14.50	$1.29B	$26.04	37.80

93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 60.3% of argenex shares are owned by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are owned by company insiders. Comparatively, 2.4% of argenex shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Alnylam Pharmaceuticals had 8 more articles in the media than argenex. MarketBeat recorded 14 mentions for Alnylam Pharmaceuticals and 6 mentions for argenex. Alnylam Pharmaceuticals' average media sentiment score of 1.24 beat argenex's score of 0.83 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	8 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
argenex	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

argenex has a net margin of 32.19% compared to Alnylam Pharmaceuticals' net margin of 15.26%. Alnylam Pharmaceuticals' return on equity of 84.93% beat argenex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%
argenex	32.19%	43.59%	36.66%

Summary

argenex beats Alnylam Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Alnylam Pharmaceuticals compare to Moderna?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Moderna (NASDAQ:MRNA) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are owned by company insiders. Comparatively, 10.8% of Moderna shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Alnylam Pharmaceuticals currently has a consensus target price of $376.67, suggesting a potential upside of 51.47%. Moderna has a consensus target price of $76.72, suggesting a potential downside of 46.71%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.88
Moderna	5 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.08

Alnylam Pharmaceuticals has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$3.71B	8.96	$313.75M	$5.38	46.22
Moderna	$1.94B	29.57	-$2.82B	-$7.99	N/A

Alnylam Pharmaceuticals has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market. Comparatively, Moderna has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market.

In the previous week, Moderna had 12 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 26 mentions for Moderna and 14 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 1.24 beat Moderna's score of 0.56 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	8 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	9 Very Positive mention(s)	8 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive

Alnylam Pharmaceuticals has a net margin of 15.26% compared to Moderna's net margin of -141.43%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%
Moderna	-141.43%	-28.30%	-19.39%

Summary

Alnylam Pharmaceuticals beats Moderna on 13 of the 17 factors compared between the two stocks.

How does Alnylam Pharmaceuticals compare to Natera?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Natera (NASDAQ:NTRA) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.

Alnylam Pharmaceuticals presently has a consensus price target of $376.67, suggesting a potential upside of 51.47%. Natera has a consensus price target of $330.83, suggesting a potential upside of 0.58%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Alnylam Pharmaceuticals is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.88
Natera	1 Sell rating(s)	4 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.83

In the previous week, Natera had 5 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 19 mentions for Natera and 14 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 1.24 beat Natera's score of 1.14 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	8 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Natera	11 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alnylam Pharmaceuticals has a net margin of 15.26% compared to Natera's net margin of -7.11%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%
Natera	-7.11%	-11.38%	-7.87%

Alnylam Pharmaceuticals has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market. Comparatively, Natera has a beta of 1.54, meaning that its share price is 54% more volatile than the broader market.

93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.9% of Natera shares are owned by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are owned by insiders. Comparatively, 5.1% of Natera shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Alnylam Pharmaceuticals has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$3.71B	8.96	$313.75M	$5.38	46.22
Natera	$2.31B	20.56	-$208.16M	-$1.36	N/A

Summary

Alnylam Pharmaceuticals beats Natera on 11 of the 16 factors compared between the two stocks.

Get Alnylam Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALNY vs. The Competition

Export

Metric	Alnylam Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$33.28B	$3.86B	$7.17B	$12.85B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	46.22	14.18	274.94	25.33
Price / Sales	8.96	1,375.01	685.45	111.15
Price / Cash	88.94	106.50	76.65	51.52
Price / Book	41.65	15.12	10.33	6.20
Net Income	$313.75M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-6.55%	-4.34%	-3.32%	-2.35%
1 Month Performance	11.04%	-0.02%	-0.41%	-2.77%
1 Year Performance	-46.62%	40.64%	19.21%	7.63%

Alnylam Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALNY Alnylam Pharmaceuticals	4.4613 of 5 stars	$248.68 +0.5%	$376.67 +51.5%	-46.9%	$33.28B	$3.71B	46.22	2,770	Positive News Analyst Forecast
VRTX Vertex Pharmaceuticals	3.5394 of 5 stars	$515.87 +0.3%	$570.83 +10.7%	+29.7%	$131.00B	$12.00B	30.04	6,400	Trending News Analyst Upgrade
REGN Regeneron Pharmaceuticals	3.8038 of 5 stars	$783.21 -1.3%	$802.18 +2.4%	+37.5%	$80.64B	$14.34B	19.36	15,410	Trending News Analyst Forecast
ARGX argenex	4.5495 of 5 stars	$991.98 +0.8%	$1,158.61 +16.8%	+28.9%	$62.15B	$5.23B	38.15	1,863
MRNA Moderna	2.1298 of 5 stars	$147.46 +7.9%	$76.72 -48.0%	+467.0%	$59.04B	$1.94B	N/A	4,700	Trending News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALNY) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alnylam Pharmaceuticals (ALNY) Competitors

ALNY vs. VRTX, REGN, ARGX, MRNA, and NTRA

How does Alnylam Pharmaceuticals compare to Vertex Pharmaceuticals?

Summary

How does Alnylam Pharmaceuticals compare to Regeneron Pharmaceuticals?

Summary

How does Alnylam Pharmaceuticals compare to argenex?

Summary

How does Alnylam Pharmaceuticals compare to Moderna?

Summary

How does Alnylam Pharmaceuticals compare to Natera?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALNY vs. The Competition

Alnylam Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alnylam Pharmaceuticals (ALNY) Competitors

ALNY vs. VRTX, REGN, ARGX, MRNA, and NTRA

How does Alnylam Pharmaceuticals compare to Vertex Pharmaceuticals?

Do analysts prefer VRTX or ALNY?

Which has more volatility and risk, VRTX or ALNY?

Which has better earnings & valuation, VRTX or ALNY?

Is VRTX or ALNY more profitable?

Do insiders & institutionals have more ownership in VRTX or ALNY?

Does the media favor VRTX or ALNY?

Summary

How does Alnylam Pharmaceuticals compare to Regeneron Pharmaceuticals?

Which has more volatility and risk, ALNY or REGN?

Which has stronger valuation & earnings, ALNY or REGN?

Is ALNY or REGN more profitable?

Does the media refer more to ALNY or REGN?

Do insiders & institutionals believe in ALNY or REGN?

Do analysts prefer ALNY or REGN?

Summary

How does Alnylam Pharmaceuticals compare to argenex?

Which has more risk and volatility, ALNY or ARGX?

Do analysts prefer ALNY or ARGX?

Which has preferable earnings and valuation, ALNY or ARGX?

Do insiders & institutionals hold more shares of ALNY or ARGX?

Does the media refer more to ALNY or ARGX?

Is ALNY or ARGX more profitable?

Summary

How does Alnylam Pharmaceuticals compare to Moderna?

Do insiders and institutionals have more ownership in ALNY or MRNA?

Do analysts rate ALNY or MRNA?

Which has higher earnings and valuation, ALNY or MRNA?

Which has more risk & volatility, ALNY or MRNA?

Does the media favor ALNY or MRNA?

Is ALNY or MRNA more profitable?

Summary

How does Alnylam Pharmaceuticals compare to Natera?

Do analysts rate ALNY or NTRA?

Does the media favor ALNY or NTRA?

Is ALNY or NTRA more profitable?

Which has more volatility & risk, ALNY or NTRA?

Do insiders & institutionals have more ownership in ALNY or NTRA?

Which has preferable earnings & valuation, ALNY or NTRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALNY vs. The Competition

Alnylam Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools